

TABLE OF CONTENTS

February 22, 2010

No. 2177

BUSINESS

- 1 FUJIFILM Embarks on Generics Business Aiming at ¥50.0 Bil. Sales in FY2014
 - FFP to Drive FUJIFILM's Group Business
 - Great Confidence in FUJIFILM Brands
 - Aiming at ¥1 Tril. Sales in Healthcare Business by FY2018
 - Reliability Is Critical in Generics Business: Toho Chairman
- 3 Novartis' Sales Up 8.2% in 2009 Driven by Diovan, Glivec
- 4 GSK's Sales Up 22% in Japan
 - GSK Launches Special Unit for Rare Diseases
- 4 JMHA to Offer DB to Its Members to Compare Purchase Prices
- 5 METI to Foster Pharma Industry as Driver of Economic Growth
- 5 **Statistics**
 - Ethical Drugs Sales Up 4.2% in December
- 6 Prospects of Incretin-Related Drugs in Japan
- 9 **BUSINESS NEWS IN BRIEF**
 - Ranbaxy to Market Prasugrel in Mexico
 - Kyowa Kirin to Introduce Research Fellow System
 - SRL to Acquire JCL
 - Toho to Enhance Pharmacy Business by Acquiring Medical Brain

REGULATORY

- 10 *Koroshio's* Proposal Regarding Generics Priced at Higher Levels Than Originals Approved as Is
 - JPA Concerned about Confusion among Pharmacists
 - Reversal of Prices Due to Current Pricing System: Mr Miura
 - Use of Higher-Priced Generics May Cost Less to Patients: Mr Miura
- 12 ¥170 Premium to Be Paid If Generics Dispensing Rate Exceeds 30%
 - ¥150 Premium If Number of Antipsychotics Used Does Not Exceed 2
 - 16 Comments Attached
 - "Exceptional" Basic Drug Dispensing Fee Up to ¥240 from ¥180
- 13 Medical Fee Determination Process Needs to Be Revised: Mr Nagatsuma
 - *Kampo* Medicines Were Not Candidates for Exclusion from Health Insurance Coverage: Mr Edano
 - Pharma Industry Can Lead Japan's Economy: Mr Hasegawa

- 14 JPA Concerned about Confusion among Pharmacists Regarding Three-Tiered Premiums
- 15 1st Meeting Held by Panel on Unapproved Drugs with Unmet Medical Needs
 - ¥7 Bil. to Be Provided to Support Development of 9 Products
- 16 DPJ Lawmaker Calls For Promotion of Pharma Industry
- 16 Cost Necessary to Revitalize Healthcare Estimated by a Team: Dr Adachi
- 17 9 New Drugs to Be Reviewed on February 26
- 17 4 Therapies Approved as Advanced Therapies
- 18 **REGULATORY NEWS IN BRIEF**
 - Daiichi Sankyo Applies for SUN Y7017 in Japan
 - Gemzar Approved for Breast Cancer in Japan: Ely Lilly
 - CDFS to Review Vectibix from Takeda

GENERICS

- 18 Mergers May Take Place between Generic Companies: Mr Sawai
- 18 **GENERICS NEWS IN BRIEF**
- 19 Taiyo to Increase Sales to Univ. Hospitals to Achieve ¥75 Bil. Sales by FY2013
 - Taiyo Yakuhin Recalls TETIPLINE Due to Adverse Reactions

SELF-MEDICATION

- 20 BI to Make SSP Wholly-Owned Subsidiary
- 20 **SELF-MEDICATION NEWS IN BRIEF**
 - More Switch OTC Drugs Are Necessary to Stimulate Market: Mr Konja
 - SSP: Sales Down Despite Good Sales of CHC Products

MEDICAL FACILITIES & NURSING CARE

- 21 Take Comprehensive Measures to Prevent VTE Including Use of Anticoagulants: Dr Sakon
- 21 Adcirca Useful for PAH with Low Incidence of ADRs: Prof. Sato
- 22 **Commentary**
 - *Koroshio* Moves to Change Its Vaccine Policy

MEDICAL DEVICES

- 23 Healthcare Is Opportunity for Investment: Mr Wachi
- 23 **Seminar**
 - Doctors Assess MRs Based on Their Expertise